LRRK2 and Parkinson disease: That said, the most advanced LRRK2 inhibitor trial has pragmatically chosen to focus recruitment of a combination of PD patients with and without LRRK2 mutations (NCT05348785), while other LRRK2-specific interventions may specifically want to recruit the subgroup who are positive for the α-syn SAA.